LGALS9 and neoplasm: The results showed that blockade of galectin-9 significantly attenuated CD8+ T-cell inhibition mediated by tumor-associated mast cells (Figure 4C), which indicated an immune-suppressive effect of tumor-associated mast cells in tumor immunity.